The study proved the superiority of the combination therapy (46% reduction in the risk of progression; p = 0.015). Based on this study, the erlotinib + Bev combination therapy was approved for the treatment of patients with advanced/metastatic NSCLC harboring EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.